Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

E-Vapor Products

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Altria reports solid earnings growth, faces legal challenges in 2024

Altria's 2024 performance showcased growth in key areas, but challenges like legal disputes and market concerns persist. The company's focus on smoke-free products and oral tobacco categories presents avenues for future growth and innovation. With a positive financial outlook and strategic initiatives like share repurchases, Altria is poised for continued success in the tobacco industry.

Altria reports resilient Q1 performance, eyes growth amidst challenges

Altria's Q1 2025 performance reflects resilience amidst challenges, with growth in key segments and a focus on profitability. The company's strategic guidance for 2025 signals a commitment to navigating uncertainties and driving sustainable growth through innovation and advocacy.

Altria reports solid Q2 earnings, focuses on brand growth

Altria's Q2 performance reflects resilience and growth in adjusted earnings per share, despite challenges such as declining cigarette volumes and regulatory pressures. The company's strengths lie in brand loyalty, shareholder value creation, and a strategic outlook that supports moderate growth and financial stability. While facing challenges like volume declines and regulatory uncertainties, Altria can capitalize on opportunities in brand expansion, supply chain optimization, and product diversification.

Altria reports Q3 growth driven by smoke-free products and collaborations

Altria's Q3 2025 performance reflects growth in adjusted earnings per share, driven by advancements in smoke-free products and stable performance in key segments. Strengths lie in the successful launch of new products, collaborations for international expansion, and commitment to shareholder returns. Challenges include market competition, regulatory pressures, and economic uncertainties, while opportunities exist in new markets, product innovation, and investor relations. Overall, Altria's financial outlook remains positive, with a focus on sustainable growth and delivering value to shareholders.

Altria reports 4.4% EPS growth, eyes smoke-free alternatives for growth

Altria's Q4 2025 earnings call showcased growth in adjusted diluted EPS, strategic milestones, and a focus on smoke-free alternatives. While facing challenges in the e-vapor segment and regulatory complexities, the company remains committed to shareholder value. Diversified revenue streams and international expansion offer promising opportunities for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.